Competitor Analysis: Pneumococcal and Streptococcal Vaccines
The present Competitive Intelligence Report about Pneumococcla and Streptococcal Vaccines provides a competitor evaluation in the field of prophylactic vaccines against infection caused by streptococcus pneumoniae (pneumococcus), Group A Streptococcus (GAS) or Group B Streptococcus (GBS) as of October 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Pneumococcal disease is a leading cause of serious illness in children and adults throughout the world. The disease is caused by a common bacterium, Streptococcus pneumoniae, or pneumococcus, a gram-positive, alpha-hemolytic, bile soluble aerotolerant anaerobe, which can attack different parts of the body. When bacteria invade the lungs, they cause the most common form of community-acquired bacterial pneumonia; when bacteria invade the bloodstream, they cause bacteremia; and when they invade the covering of the brain, they cause meningitis. Pneumococci may also cause otitis media (middle ear infection) and sinusitis.
The four major commercially available pneumococcal vaccines posted worldwide sales of more than US$ 5 bln in 2011 indicating the strong interest in the healthcare sector and the vaccine industry.
The report includes a compilation of currently active projects in development of vaccines targeting pneumococcus (Streptococcus pneumoniae), Group A Streptococcus (GAS) or Group B Streptococcus (GBS) for prophylaxis of streptococcal infections. In addition, the report lists company-specific R&D pipelines of Pneumococcal and Streptococcal Vaccines. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Pneumococcal disease is a leading cause of serious illness in children and adults throughout the world. The disease is caused by a common bacterium, Streptococcus pneumoniae, or pneumococcus, a gram-positive, alpha-hemolytic, bile soluble aerotolerant anaerobe, which can attack different parts of the body. When bacteria invade the lungs, they cause the most common form of community-acquired bacterial pneumonia; when bacteria invade the bloodstream, they cause bacteremia; and when they invade the covering of the brain, they cause meningitis. Pneumococci may also cause otitis media (middle ear infection) and sinusitis.
The four major commercially available pneumococcal vaccines posted worldwide sales of more than US$ 5 bln in 2011 indicating the strong interest in the healthcare sector and the vaccine industry.
The report includes a compilation of currently active projects in development of vaccines targeting pneumococcus (Streptococcus pneumoniae), Group A Streptococcus (GAS) or Group B Streptococcus (GBS) for prophylaxis of streptococcal infections. In addition, the report lists company-specific R&D pipelines of Pneumococcal and Streptococcal Vaccines. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Index
- Pneumococcal Vaccines
- Group A Streptococcus (GAS) Vaccines
- Group B Streptococcus (GBS) Vaccines & Antibodies
- Corporate Pneumococcal and Streptococcal Vaccine R&D Pipelines
- About La Merie
More Publications
Competitor Analysis: Dengue Virus Vaccines and Therapeutics
US$ 243.00
July 2012
27 pages
Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives)
US$ 662.00
October 2013
92 pages
Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics
US$ 394.00
May 2012
46 pages
Competitor Analysis: P. aeruginosa Vaccines and Therapeutics
US$ 230.00
June 2010
22 pages
Competitor Analysis: Herpes Virus Vaccines and Therapeutics
US$ 396.00
December 2012
56 pages
